Evvy raises $40M Series B to scale AI women’s health diagnostics

Evvy said it closed an oversubscribed $40 million Series B led by Catalio Capital Management. The women’s health company says the capital will validate a new generation of EvvyAI-powered diagnostic and care models across underserved conditions, starting with fertility, on top of its clinical-grade vaginal microbiome dataset.

Same-day HEALTH primary that a women’s-health diagnostics company closed a Catalio-led $40 million Series B to validate EvvyAI models starting with fertility — not another general-purpose chatbot, and not an FDA clearance.

Evvy, a women’s-health company, announced an oversubscribed $40 million Series B led by Catalio Capital Management. Series B is a later growth-funding round — after seed and Series A. Oversubscribed means more investors wanted in than the company took. The company release, carried on Business Wire and dated September 15, 2026, 9:00 AM EDT, is the filing event. These are company claims.

New investors on the wire: Catalio Capital Management, Rethink Impact, Muse Capital, and Alumni Ventures. Existing investors named: LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital, and Flywheel Ventures. None was printed.

Founders, as the same release has it: Priyanka Jain, Laine Bruzek, and Pita Navarro, founded in 2021. Jain is co-founder and chief executive.

Product, still company: a vaginal microbiome platform plus EvvyAI, its machine-learning engine. A microbiome is the community of microbes living in a body site. Evvy says patients get at-home testing, personalized treatment, and longitudinal biomarker tracking — watching the same biological markers over time. Every test, the company says, is powered by CLIA-certified, New York State CLEP-approved metagenomic sequencing. CLIA is the U.S. Lab-quality rulebook. CLEP is New York’s extra lab-approval program, one of the stricter U.S. Lab licenses. Metagenomic sequencing reads the DNA in a sample to see which microbes are there, not just a short list of usual suspects. Tests are ordered and interpreted by licensed clinicians and matched with prescription plans tailored to results and health history where relevant.

Company scale claims: more than 100,000 patients and 3,000 practitioners. The company calls its dataset the world’s largest proprietary, clinical-grade record of the vaginal microbiome and women’s health outcomes. The announcement graf says the platform has led to 13 peer-reviewed publications and abstracts, the identification of novel bacterial vaginosis — BV — subtypes, and the discovery of hundreds of previously uncatalogued vaginal microbiome genomes. The About box also says the Vaginal Health Test uncovers 700-plus microbes with one at-home swab. File 100,000-plus, 3,000, 13, the BV-subtype and genome lines, and 700-plus as Evvy’s. Extra About-box publication counts stay in Sources.

Company-attributed outcome stats, still the wire’s: most patients come with vaginal symptoms or fertility challenges that standard testing has failed to explain. In the U.S., the company says, vaginal symptoms are a leading reason women seek care, yet patients face 50-percent-plus misdiagnosis rates and 60-percent-plus recurrence rates in traditional settings. Licensed clinicians using Evvy’s platform and EvvyAI, the company says, deliver a diagnosis to 90-percent-plus of symptomatic patients and a roughly 50-percent-plus cut in BV recurrence through targeted protocols, with those improvements “validated in peer-reviewed research.”. The Sep 15 wire does not claim FDA clearance for EvvyAI.

Capital use, company: clinical validation of new EvvyAI-powered diagnostic and care models across women’s-health conditions that Evvy says collectively cost the system more than $180 billion in underserved outcomes; expand distribution through physicians and partner channels; and continue a collaboration with US Fertility, which the company calls the nation’s largest fertility-clinic network, on the vaginal microbiome in fertility and reproductive health.

Named voices on the wire: Jacob Vogelstein, co-founder and managing partner at Catalio Capital Management; and Priyanka Jain, co-founder and CEO. Their quotes are color only and stay in Sources. This is not investment advice.

Plain English for the rest of the card: Series B = later growth funding after seed and Series A. Microbiome = the community of microbes living in a body site. Metagenomic sequencing = reading the DNA in a sample to see which microbes are there. CLIA = U.S. lab-quality rules. CLEP = New York State’s extra lab-approval program. EvvyAI = Evvy’s machine-learning engine for those biological datasets. Longitudinal tracking = watching the same markers over time.